1-1 of 1
Keywords: Irbesartan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Serum Levels of the Advanced Glycation End Products N ε -Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

Available to Purchase
Subject Area:
Nephrology
Martin Busch, Sybille Franke, Gunter Wolf, Richard D. Rohde, Günter Stein
Journal: Nephron Clinical Practice
Nephron Clinical Practice (2008) 108 (4): c291–c297.
https://doi.org/10.1159/000127838
Published Online: 24 April 2008
...Martin Busch; Sybille Franke; Gunter Wolf; Richard D. Rohde; Günter Stein Background/Aims: The aim of this post-hoc analysis of a prospective study in patients with type 2 diabetic nephropathy was to investigate whether treatment with the angiotensin II type 1 receptor blocker irbesartan leads...
View articletitled, Serum Levels of the Advanced Glycation End Products N ε -Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension
Open the PDF for Serum Levels of the Advanced Glycation End Products N ε -Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension in another window